Vivani Medical, Inc. VANI
1.01 USD +0.03 (+2.70%)
Regular-session close
1.01 0.00 0.00%
Pre-market · Nov 16, 8:27 AM ET
0.8882 Day range 1.03
0.80 52-week range 1.66
- YTD
- -17.89%
- 1 year
- -25.74%
News
globenewswire.com Vivani Medical Announces Private Placement Equity Financing ALAMEDA, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting…
benzinga.com Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027 Vivani Medical Inc. (NASDAQ:VANI) stock soared on Thursday after reporting positive topline results from its Phase 1 SLIM-1 clinical trial, showing that its experimental semaglutide implant matched…
benzinga.com Vivani Medical Advances Long-Acting Semaglutide Implant Toward Phase 2 Trial in 2027 Vivani Medical reports Phase 1 results for its NPM-139 implant, matching Wegovy weight loss without treatment-related side effects.
globenewswire.com Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects Strong NPM-139 safety and tolerability profile: -0 of 10 NPM-139 subjects experienced adverse events reported as treatment related -5 of 10 Wegovy subjects (control group) experienced adverse events…benzinga.com Vivani Medical Q3 EPS $(0.08), Inline Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 27.27 percent increase over losses of $(0.11) per share from the same…
globenewswire.com Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update Top-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated…
